{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T14:42:12Z","timestamp":1751467332774,"version":"3.40.4"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T00:00:00Z","timestamp":1383523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Multicenter trials have demonstrated that in patients with sinus rhythm ivabradine is effective in the therapy of ischemic heart disease and of impaired left ventricular systolic function. Ivabradine is ineffective in atrial fibrillation. Many patients with symptomatic heart failure have diastolic dysfunction with preserved left ventricular systolic function, and many have asymptomatic paroxysmal atrial fibrillation. Ivabradine is not indicated in these conditions, but it happens that it is erroneously used. Digoxin is now considered an outdated and potentially dangerous drug and while effective in the mentioned conditions, is rarely used. The aim of the study was to compare the therapeutic effects of ivabradine in diastolic heart failure with preserved left ventricular systolic function. Patients were assigned to ivabradine or digoxin according to a randomization cross-over design. Data were single-blind analyzed. The analysis was performed using an intention-to-treat method. Forty-two coronary patients were selected. In spite of maximally tolerated therapy with renin-antagonists, diuretics and \u03b2-blockers, they had congestive diastolic heart failure with preserved systolic function. Both ivabradine and digoxin had positive effects on dyspnea, Nterminal natriuretic peptide, heart rate, duration of 6-min. walk-test and signs of diastolic dysfunction, but digoxin was high-statistically more effective. Side-effects were irrelevant. Data were obtained in a single-center and from 42 patients with ischemic etiology of heart failure. The number of patients is small and does not allow assessing mortality. In coronary patients with symptomatic diastolic heart failure with preserved systolic function low-dose digoxin was significantly more effective than ivabradine and is much cheaper. One should be more critical about ivabradine and low-dose digoxin in diastolic heart failure. To avoid possible negative effects on the cardiac function and a severe reduction of the cardiac output the resting heart rate should not be decreased to &lt;65 beats\/min.<\/jats:p>","DOI":"10.4081\/cp.2013.e29","type":"journal-article","created":{"date-parts":[[2013,11,4]],"date-time":"2013-11-04T16:35:28Z","timestamp":1383582928000},"page":"e29","source":"Crossref","is-referenced-by-count":12,"title":["Comparison Between Ivabradine and Low-Dose Digoxin in the Therapy of Diastolic Heart Failure with Preserved Left Ventricular Systolic Function"],"prefix":"10.3390","volume":"3","author":[{"given":"Giuseppe","family":"Cocco","sequence":"first","affiliation":[{"name":"Cardiology Private Office, Rheinfelden, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Jerie","sequence":"additional","affiliation":[{"name":"Cardiology Private Office, Rheinfelden, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2013,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"D19","DOI":"10.1093\/eurheartj\/sup014","article-title":"A step further with ivabradine: SIGNIfY (Study assessIngG the morbiditymortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease)","volume":"11","author":"Ferrari","year":"2009","journal-title":"Eur Heart J"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebocontrolled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/eurheartj\/eht101","article-title":"Effect of ivabradine in patients with left-ventricular systolic dysfunction: a polled analysis of individual patients: data from the BEAUTIFUL and SHIFT trials","volume":"34","author":"Fox","year":"2013","journal-title":"Eur Heart J"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJM198012183032503","article-title":"Longterm digitalis therapy improves left ventricular function in heart failure","volume":"303","author":"Arnold","year":"1980","journal-title":"N Engl J Med"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5694\/j.1326-5377.2003.tb05445.x","article-title":"Digoxin in heart failure and cardiac arrhythmias","volume":"179","author":"Campbell","year":"2003","journal-title":"Med J Aust"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/bmj.39365.511076.BE","article-title":"Rate control in permanent atrial fibrillation","volume":"335","author":"Nikolaidou","year":"2007","journal-title":"BMJ"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/eurheartj\/ehi686","article-title":"Rehabilitating digoxin","volume":"27","author":"Brophy","year":"2006","journal-title":"Eur Heart J"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIGOXIN trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/eurheartj\/ehs004","article-title":"Should we SHIFT our thinking about digoxin? Observations on ivabradine and heart rate reduction in heart failure","volume":"33","author":"Castagno","year":"2012","journal-title":"Eur Heart J"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","article-title":"ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)","volume":"10","author":"Dickstein","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2006.07.009","article-title":"ACC\/AHA\/ESC 2006 Guidelines for the management of patients with atrial fibrillation-executive summary","volume":"48","author":"Fuster","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.NAJ.0000427886.56289.e3","article-title":"Digoxin use increased mortality in patients with AF","volume":"113","author":"Singh","year":"2013","journal-title":"AJN"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Whitbeck, MG, Charnigo, RJ, and Khairy, P (2013). Increased mortality among patients taking digoxin: analysis from the AFFIRM study. Eur Heart J.","DOI":"10.1093\/eurheartj\/ehs348"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1093\/eurheartj\/eht087","article-title":"When \u2018digoxin use\u2019 is not the same as \u2018digoxin use\u2019: lesson from the AFFIRM trial","volume":"34","author":"Murpy","year":"2013","journal-title":"Eur Heart H"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199307013290101","article-title":"Withdrawal of digoxin therapy from patients treated with angiotensin-converting enzyme inhibitors","volume":"329","author":"Packer","year":"1993","journal-title":"N Engl J Med"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0735-1097(95)00140-U","article-title":"Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure","volume":"26","author":"Ward","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1476-7120-5-16","article-title":"Current clinical applications of spectral tissue Doppler echocardiography (E\/E\u2019 ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function","volume":"5","author":"Arques","year":"2007","journal-title":"Cardiovasc Ultrasound"},{"key":"ref_18","first-page":"e46","article-title":"Heart disease and stroke statistics. 2010 update: a report from the American Heart Association","volume":"121","author":"Adams","year":"2010","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.80.6.1557","article-title":"Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group","volume":"80","author":"Anderson","year":"1989","journal-title":"Circulation."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9343(99)80348-9","article-title":"The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study","volume":"98","author":"Krahn","year":"1995","journal-title":"Am J Med"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","article-title":"How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure wit with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology","volume":"28","author":"Paulus","year":"2007","journal-title":"Eur Heart J"},{"key":"ref_22","first-page":"919","article-title":"The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure","volume":"132","author":"Guyatt","year":"1985","journal-title":"Can Med Assoc J"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.echo.2009.05.020","article-title":"Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation","volume":"22","author":"Douglas","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2008.02.067","article-title":"Echocardiographic assessment of left ventricular diastolic function and filling pressure in atrial fibrillation","volume":"101","author":"Finstuen","year":"2008","journal-title":"Am J Cardiol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1751-7176.2010.00380.x","article-title":"Physical exercise with weight reduction lowers blood pressure and improves abnormal left ventricular relaxation in pharmacologically treated hypertensive patients","volume":"13","author":"Cocco","year":"2011","journal-title":"J Clin Hypertens"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4065\/mcp.2010.0682","article-title":"Left atrial volume index is predictive of mortality independent of left ventricular geometry in a large clinical cohort with preserved ejection fraction","volume":"8","author":"Patel","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"ref_27","first-page":"35","article-title":"The basic mechanism of inotropic action of digoxin glycosides","volume":"15","author":"Smith","year":"1984","journal-title":"J Pharmacol"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.clinicsandpractice.org\/index.php\/cp\/article\/viewFile\/597\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2039-7283\/3\/2\/e29\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T07:43:29Z","timestamp":1745394209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/3\/2\/e29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,4]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,5]]}},"alternative-id":["cp.2013.e29"],"URL":"https:\/\/doi.org\/10.4081\/cp.2013.e29","relation":{},"ISSN":["2039-7283"],"issn-type":[{"type":"electronic","value":"2039-7283"}],"subject":[],"published":{"date-parts":[[2013,11,4]]}}}